HD-OPM Archive
Topics › Cancer

RAS inhibitors are changing pancreatic cancer treatment, say Dana-Farber researchers

Louis Nervegna · Jun 01, 2026 · ♥ 4 reactions · 0 comments · original Facebook post
Cancer
AI summary & key facts

Louis shares a Dana-Farber explainer on RAS inhibitors for pancreatic cancer with a quote from Dr. Brian Wolpin that this drug class could open the way to many other cancers. Mostly a pointer to an institutional page.

“Pancreas cancer may be the first for this drug, but there will be others. Now the floodgates open!”

— Dr. Brian Wolpin, Dana Farber

The RAS family of proteins is known to be mutated in ways that drive the growth of many forms of cancer.

#pancreaticcancerHD #daraxonrasibHD #cancerHD #rasHD #ascoHD #rasolute302HD

Research cited

New medicines called RAS inhibitors are dramatically changing the future of pancreatic cancer treatment. Our researchers are helping lead clinical trials studying these promising therapies for patients with pancreatic cancer. Learn how RAS inhibitors work, who may benefit and what and research is underway. ⬇️

← newer: Daraxonrasib extends survival in treated metastatic pancreatolder: ACC guidance backs AI plaque analysis on CT angiography to g →